Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.provenance | Comisión de Investigaciones Científicas | - |
| dc.contributor | McCarthy, Antonio Desmond | - |
| dc.contributor | Cortizo, Ana María | - |
| dc.contributor | Sedlinsky, Claudia | - |
| dc.creator | McCarthy, Antonio Desmond | - |
| dc.creator | Cortizo, Ana María | - |
| dc.creator | Sedlinsky, Claudia | - |
| dc.date | 2016 | - |
| dc.date.accessioned | 2019-04-29T16:07:46Z | - |
| dc.date.available | 2019-04-29T16:07:46Z | - |
| dc.date.issued | 2016 | - |
| dc.identifier | http://digital.cic.gba.gob.ar/handle/11746/4901 | - |
| dc.identifier.uri | http://rodna.bn.gov.ar:8080/jspui/handle/bnmm/309908 | - |
| dc.description | Patients with long-term type 1 and type 2 diabetes or “diabetic osteopathy”. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatments can secondarily affect bone metabolism. Adenosine monophosphateactivated protein kinase (AMPK) modulates multiple metabolic pathways and acts as a sensor of the cellular energy status; recent evidence suggests a critical role for AMPK in bone homeostasis. In addition, AMPK activation is believed to mediate most clinical effects of the insulin-sensitizer metformin. Over the past decade, several research groups have investigated the effects of metformin on bone, providing a considerable body of pre-clinical (in vitro , ex vivo and in vivo ) as well as clinical evidence for an anabolic action of metformin on bone. However, two caveats should be kept in mind when considering metformin treatment for a patient with type 2 DM at risk for diabetic osteopathy. In the first place, metformin should probably not be considered an antiosteoporotic drug; it is an insulin sensitizer with proven macrovascular benefits that can secondarily improve bone metabolism in the context of DM. Secondly, we are still awaiting the results of randomized placebo-controlled studies in humans that evaluate the effects of metformin on bone metabolism as a primary endpoint. | - |
| dc.format | application/pdf | - |
| dc.format | 13 p. | - |
| dc.language | spa | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.rights | Attribution 4.0 International (BY 4.0) | - |
| dc.source | reponame:CIC Digital (CICBA) | - |
| dc.source | instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Aires | - |
| dc.source | instacron:CICBA | - |
| dc.source.uri | http://digital.cic.gba.gob.ar/handle/11746/4901 | - |
| dc.subject | Ciencias Químicas | - |
| dc.title | Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy? | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/submittedVersion | - |
| dc.type | info:ar-repo/semantics/articulo | - |
| Aparece en las colecciones: | Comisión de Investigaciones Científicas de la Prov. de Buenos Aires | |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.